![]() |
Volumn 56, Issue 9, 2005, Pages 1056-1058
|
Potential effects of the new medicare drug benefit on pricing for psychotropic medications
|
Author keywords
[No Author keywords available]
|
Indexed keywords
PSYCHOTROPIC AGENT;
COMMERCIAL PHENOMENA;
COMPETITION;
DRUG COST;
DRUG DEVELOPMENT;
DRUG FORMULATION;
DRUG RESEARCH;
FINANCIAL MANAGEMENT;
LAW;
MANAGED CARE;
MEDICAL FEE;
MEDICARE;
MENTAL DISEASE;
REIMBURSEMENT;
SHORT SURVEY;
ARTICLE;
COST;
COST CONTROL;
DRUG INDUSTRY;
ECONOMICS;
HEALTH INSURANCE;
HUMAN;
INTERPERSONAL COMMUNICATION;
STATISTICS;
UNITED STATES;
COST CONTROL;
COSTS AND COST ANALYSIS;
DRUG COSTS;
DRUG INDUSTRY;
HUMANS;
INSURANCE, PHARMACEUTICAL SERVICES;
MEDICARE;
NEGOTIATING;
PSYCHOTROPIC DRUGS;
UNITED STATES;
|
EID: 24644521448
PISSN: 10752730
EISSN: None
Source Type: Journal
DOI: 10.1176/appi.ps.56.9.1056 Document Type: Short Survey |
Times cited : (4)
|
References (8)
|